166170-15-6

Usage

Uses

Used in Pharmaceutical Industry:
(R)-N-BOC-2-methylproline is used as a key intermediate for the development of new drugs, leveraging its role in the synthesis of bioactive molecules. Its protected amine group facilitates the creation of complex peptide structures that are vital for medicinal chemistry.
Used in Organic Synthesis:
(R)-N-BOC-2-methylproline is used as a building block in organic synthesis for constructing complex organic compounds, taking advantage of its protected amine group to allow for selective reactions.
Used as a Chiral Auxiliary in Asymmetric Synthesis:
(R)-N-BOC-2-methylproline is utilized as a chiral auxiliary to prepare enantiomerically pure compounds, which is essential for the production of single-enantiomer drugs and other chiral molecules with specific biological activities.

Upstream product

• 24424-99-5 di-tert-butyl dicarbonate 
• 63399-77-9 (R)-2-Methyl-1-azacyclopentan-2-carbonsaeure 
• 912445-03-5 (R)-2-benzyl 1-tert-butyl 2-methylpyrrolidine-1,2-dicarboxylate 

Downstream Products

• 1207754-99-1 tert-butyl (R)-2-(hydroxymethyl)-2-methylpyrrolidine-1-carboxylate 
• 912444-00-9 veliparib 
• 1223404-98-5 (R)-tert-butyl 2-(5-((R)-2-(2,5-difluorophenyl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidin-3-ylcarbamoyl)-2-methylpyrrolidine-1-carboxylate 

Relevant academic research and scientific papers

ALKYNYL QUINAZOLINE COMPOUNDS

The present disclosure relates to compounds of Formula (I'): and pharmaceutically acceptable salts and stereoisomers thereof. The present disclosure also relates to methods of preparation these compounds, compositions comprising these compounds, and methods of using them in the prevention or treatment of abnormal cell growth in mammals, especially humans.

Synthesis of (R)-Boc-2-methylproline via a Memory of Chirality Cyclization. Application to the Synthesis of Veliparib, a Poly(ADP-ribose) Polymerase Inhibitor

(R)-Boc-2-methylproline (3a) was synthesized in good yield with excellent stereochemical control from alanine benzyl ester hydrochloride 11. The process, which is based on a modification of one described by Kawabata, proceeds in four steps and requires no

Synthetic method for novel chiral ligand, metal chelate, multiple unnatural amino acids, maraviroc and key intermediate thereof

The invention discloses a synthetic method for a novel chiral ligand, a metal chelate, multiple unnatural amino acids, maraviroc and a key intermediate thereof. According to the synthetic method, (R)-2-methylproline is selected as a starting material, and asymmetrical resolution is induced by utilizing a nickel chelate, so that (S)-beta3-amino acid is obtained, and (S)-3-amino-3-phenylpropionic acid is taken as the key intermediate for synthesizing maraviroc, so that yield is high, and ee value reaches more than or equal to 98.2%. The method disclosed by the invention has the advantages that source of raw materials is wide, conditions of a synthetic process are mild, control is easy, and optical purity of products is high.

DIHYDROPYRIDAZINE-3,5-DIONE DERIVATIVE AND PHARMACEUTICALS CONTAINING THE SAME

The present invention provides a dihydropyridazine-3,5-dione derivative or a salt thereof, or a solvate of the compound or the salt, a pharmaceutical drug, a pharmaceutical composition, a sodium-dependent phosphate transporter inhibitor, and a preventive and/or therapeutic agent for hyperphosphatemia, secondary hyperparathyroidism, chronic renal failure, chronic kidney disease, and arteriosclerosis associated with vascular calcification comprising the compound as an active ingredient, and a method for prevention and/or treatment.

Discovery of 2-alkyl-1-arylsulfonylprolinamides as 11β-hydroxysteroid dehydrogenase type 1 inhibitors

On the basis of scaffold hopping, a novel series of 2-alkyl-1- arylsulfonylprolinamides was discovered as 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD-1) inhibitors. A representative compound 4ek, obtained through SAR and structure optimization studies, demonstrates excellent in vitro potency against 11β-HSD-1 and dose-dependent in vivo inhibition of 11β-HSD-1 in a prednisone/prednisolone transformation biomarker study in mice.

1H-benzimidazole-4-carboxamides substituted with a quaternary carbon at the 2-position are potent PARP inhibitors

Compounds of Formula (I) inhibit the PARP enzyme and are useful for treating a disease or a disorder associated with PARP. Also disclosed are pharmaceutical compositions comprising compounds of Formula (I), methods of treatment comprising compounds of For